

**EPF wishes to thank the European Commission** for its support in 2019 in relation to EPF's role in the following projects

	EC Contribution used in 2019	% of total income
<b>TOTAL European Commission support to projects 2019</b>	<b>€ 188,009.61</b>	
CHRODIS +	€ 25,190.75	0.9%
ComparEU	€ 31,468.16	1.1%
DigitalHealthEurope	€ 24,273.65	0.9%
EFO EUPATI	€ 82,853.30	3.0%
EHDEN	€ 13,402.80	0.5%
EU-PEARL	€ 1,316.32	0.0%
IMMUCAN	€ 5,914.48	0.2%
PREFER	€ 3,590.15	0.1%

**EPF wishes to thank the following donors** for their support:

	Contribution to the Operations	% of total income
<b>Operational &amp; Engagement - work plan 2019/ Project Development 2019</b>	<b>€ 855,150.00</b>	
European Commission	€ -	0.0%
AbbVie	€ 35,000.00	1.3%
Amgen	€ 35,000.00	1.3%
Celgene	€ 30,000.00	1.1%
CSL Behring	€ 10,000.00	0.4%
Edwards Lifescience SA	€ 25,000.00	0.9%
Eli Lilly	€ 15,000.00	0.5%
Gilead Sciences Europe	€ 40,000.00	1.4%
Grunenthal	€ 5,000.00	0.2%
GSK	€ 30,000.00	1.1%
Janssen	€ 50,000.00	1.8%
Medicines for Europe	€ 20,000.00	0.7%
MSD	€ 80,000.00	2.9%
Novartis Pharma AG	€ 100,000.00	3.6%
Pfizer Inc	€ 25,000.00	0.9%
Philips	€ 10,000.00	0.4%
F. Hoffman-La Roche	€ 50,000.00	1.8%
Sanofi Aventis	€ 50,000.00	1.8%
Servier	€ 10,000.00	0.4%
Takeda	€ 40,000.00	1.4%
Teva	€ 110,000.00	4.0%
UCB	€ 25,000.00	0.9%
Vertex	€ 40,000.00	1.4%
Membership	€ 20,150.00	0.7%

<b>Capacity Building Programme 2019</b>	<b>€ 480,655.26</b>	
	Contribution to the CBP	% of total income
Alexion	€ 14,000.00	0.5%
Amgen	€ 5,000.00	0.2%
Baxter	€ 10,000.00	0.4%
Biogen	€ 20,000.00	0.7%
EFPIA (DSL)	€ 136,655.26	4.9%
EFPIA/ Vaccines Europe	€ 65,000.00	2.3%
EIT Health (DSL)	€ 20,000.00	0.7%
ENHA	€ 10,000.00	0.4%
GSK	€ 30,000.00	1.1%
Kyowa Kirin	€ 10,000.00	0.4%
LEO Pharma	€ 15,000.00	0.5%
Medtech (DSL)	€ 10,000.00	0.4%
Merck	€ 35,000.00	1.3%
MNI (Medical Nutrition International)	€ 20,000.00	0.7%
Novo-nordisk	€ 30,000.00	1.1%
Pfizer Inc	€ 25,000.00	0.9%
Teva	€ 25,000.00	0.9%

<b>Patients Active in Research and Dialogue for an Improved Generation of Medicine "PARADIGM"</b>	<b>€ 427,508.74</b>	
---	---------------------	--

		% of total income
Innovative Medicines Initiative (IMI JU) PARADIGM Funding	€ 282,112.93	10.2%
Industry cash contribution (Amgen, Lundbeck, MSD, Pfizer, VFA)	€ 145,395.81	5.2%
<b>Patient Academy on Therapeutic Innovation "EUPATI Programme" 2017-2019</b>	<b>€ 238,022.04</b>	
		% of total income
Industry consortium 2017-2019 (AbbVie, Amgen, AstraZeneca UK, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DIA, F. Hoffmann-La Roche, GSK, Janssen, LEO Pharma, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Shire, UCB, Takeda, VFA)	€ 238,022.04	8.6%
<b>CONGRESS 2019</b>	<b>€ 541,110.00</b>	
AbbVie	€ 20,000.00	0.7%
Alexion	€ 13,500.00	0.5%
Baxter	€ 10,000.00	0.4%
Bayer	€ 10,000.00	0.4%
BMS	€ 25,000.00	0.9%
Boehringer	€ 20,000.00	0.7%
Celgene	€ 25,000.00	0.9%
EFPIA	€ 50,000.00	1.8%
EIT Health	€ 20,000.00	0.7%
Fresenius Kabi	€ 10,000.00	0.4%
Janssen	€ 40,000.00	1.4%
Kyowa Kirin	€ 10,000.00	0.4%
LEO Pharma	€ 10,000.00	0.4%
Merck	€ 40,000.00	1.4%
MYLAN	€ 10,000.00	0.4%
Novartis Pharma AG	€ 40,000.00	1.4%
Novo Nordisk	€ 25,000.00	0.9%
F. Hoffman-La Roche	€ 10,000.00	0.4%
Servier	€ 15,000.00	0.5%
Takeda	€ 15,000.00	0.5%
UCB	€ 10,000.00	0.4%
Participation Fees	€ 106,990.00	3.9%
Membership	€ 5,620.00	0.2%
<b>Other income</b>	<b>€ 41,857.77</b>	<b>1.5%</b>
<b>TOTAL INCOME 2019</b>	<b>€ 2,772,313.42</b>	